Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 239-243

  Cakirca, Mustafa ^a   Karatoprak, Cumali ^a   Zorlu, Mehmet ^a   Kiskac, Muharrem ^a   Kanat, Mustafa ^b   Cikrikcioglu, Mehmet Ali ^a   Soysal, Pinar ^c   Hursitoglu, Mehmet ^d   Camli, Ahmet Adil ^a   Erkoc, Reha ^a   Abdul Ghani, Muhammad ^e  

^a BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^b ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d Kanuni Sultan Suleyman Training and Research Hospital   (Turkey)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Asymmetric Dimethylarginine (ADMA); Dipeptidyl peptidase 4 (DPP 4) inhibitor; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; N(G),N(G) DIMETHYLARGININE; TRIACYLGLYCEROL; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; ARGININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG COMBINATION; N,N-DIMETHYLARGININE; NITRIC OXIDE; NITRILE; PYRROLIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; MIDDLE AGED;

ADAMANTANE; ADULT; AGED; ARGININE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; FEMALE; FIBRINOGEN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRIC OXIDE; NITRILES; PYRROLIDINES;

EID: 84894777786     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S52545     Document Type: Article

References (15)

1. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88-136.
2. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512.
3. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol. 2002;172(2):355-362.
4. Cavusoglu E, Ruwende C, Chopra V, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis. 2010;210(1):226-231.
5. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2008;1(3):153-160.
6. Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension. 2011;58(1):93-98.
7. Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb. 2011;18(9):774-783.
8. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardio protective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121-137.
9. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572-575.
10. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6(2):82-90.
11. Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol. 2011;10:85.
12. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther. 2011;25(1):13-20.
13. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8): 962-965.
14. Ku HC, Chen WP, Su MJ. DPP4 deficiency preserves cardiac function via GLP-1 signalling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(2): 197-207.
15. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59(4): 1063-1073.